A Rare Disease Drug Developer Tries to Earn Its Stripes

Neil McFarlane, president and CEO of Zevra Therapeutics, discusses the rare lysosomal storage disorder Niemann Pick disease type C, the FDA’s upcoming decision on whether to approve the drug, and its broader efforts to build itself into a rare disease therapeutics company. @globalgenes #RARECast